News - Page 36 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Psychedelic Research Bulletin: September 2023

Psychedelic Research Bulletin: September 2023

Post published:October 4, 2023
Post category:Psychedelics Research Review

Read more about the article Sunstone Therapies Announces Expansion of Innovative Dyad Study

Sunstone Therapies Announces Expansion of Innovative Dyad Study

Post published:October 3, 2023
Post category:Press Release

Read more about the article Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Post published:October 3, 2023
Post category:Press Release

Read more about the article atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Post published:October 3, 2023
Post category:Press Release

Read more about the article Disposition of Common Shares of Small Pharma Inc.

Disposition of Common Shares of Small Pharma Inc.

Post published:October 3, 2023
Post category:Press Release

Read more about the article GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Post published:September 29, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics?

Psychedelic Bulletin #146: Numinus Drops Lab, Consolidates Clinics; Study Suggests DMT Safe and Effective Alongside SSRI; Preprint Calls Intracellular Theory of Psychedelic-induced Neuroplasticity Into Question; A Cole Memo for Psychedelics?

Post published:September 29, 2023
Post category:Psychedelic Bulletin

Read more about the article FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL

FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL

Post published:September 29, 2023
Post category:Press Release

Read more about the article Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program

Canadian Veteran Receives Approval for APEX’s Psilocybin Therapy Through Health Canada’s Special Access Program

Post published:September 27, 2023
Post category:Press Release

Read more about the article PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)

Post published:September 27, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.